51163-29-2

Usage

Uses

2,4-Dimethylphenyl isocyanate is used as a pharmaceutical intermediate.

InChI:InChI=1/C9H9NO/c1-7-3-4-9(10-6-11)8(2)5-7/h3-5H,1-2H3

Upstream product

• 2990-02-5 1-(2,4-dimethylphenyl)urea 
• 35601-95-7 (2,4-dimethyl-phenyl)-carbamic acid ethyl ester 
• 75-44-5 phosgene 
• 95-68-1 2,4-Xylidine 
• 89-87-2 2,4-dimethylnitrobenzene 
• 201230-82-2 carbon monoxide 
• 7647-01-0 hydrogenchloride 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 131866-69-8 (2,4-dimethyl-phenyl)-carbamic acid-(2-diethylamino-ethyl ester) 
• 101793-23-1 3-(2,4-dimethyl-phenyl)-6,8-dimethyl-1H-quinazoline-2,4-dione 
• 50909-96-1 1-(2,4-Dimethyl-phenyl)-3-(1-methyl-1-p-tolyl-ethyl)-urea 
• 42609-72-3 1-(2,4-Dimethyl-phenyl)-3-(1-methyl-1-o-tolyl-ethyl)-urea 
• 42609-68-7 1-(2,4-Dimethyl-phenyl)-3-(1-methyl-1-m-tolyl-ethyl)-urea 
• 34207-63-1 C₂₁H₂₅N₃O₄ 
• 34204-01-8 C₂₁H₂₅N₃O₄ 
• 34203-96-8 C₂₁H₂₅N₃O₄ 
• 38008-40-1 (2,4-Dimethyl-phenyl)-carbamic acid 3-ethylsulfanylcarbonylamino-phenyl ester 
• 32608-33-6 (2,4-Dimethyl-phenyl)-carbamic acid prop-2-ynyl ester 
• 22541-11-3 C₁₁H₁₇N₃O 
• 53777-65-4 1-(2,4-Dimethyl-phenyl)-3-{2-[2-hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-ethyl}-urea 
• 22546-35-6 C₁₀H₁₅N₃O 
• 32496-30-3 (2,4-Dimethyl-phenyl)-carbamic acid 1-methyl-prop-2-ynyl ester 

Relevant academic research and scientific papers

Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives

Based on the structural modification of molecular-targeted agent sorafenib, a series of quinazolinyl-arylurea derivatives were synthesized and evaluated for their anti-proliferative activities against six human cancer cell lines. Compared with other cell lines tested, T24 was more sensitive to most compounds. Compound 7j exhibited the best profile with lower IC50 value and favorable selectivity. In this study, we focused on 7j-induced death forms of T24 cells and tried to elucidate the reason for its potent proliferative inhibitory activity. Compound 7j treatment could trigger three different cell death forms including apoptosis, ferroptosis, and autophagy; which form would occur depended on the concentrations and incubation time of 7j: (1) Lower concentrations within the initial 8 h of 7j treatment led to apoptosis-dependent death. (2) Ferroptosis and autophagy occurred in the case of higher concentrations combining with extended incubation time through effectively regulating the Sxc?/GPx4/ROS and PI3K/Akt/mTOR/ULK1 pathways, respectively. (3) The above death forms were closely associated with intracellular ROS generation and decreased mitochondrial membrane potential induced by 7j. In molecular docking and structure-activity relationship analyses, 7j could bind well to the active site of the corresponding receptor glutathione peroxidase 4 (GPx4). Compound 7j could be a promising lead for molecular-targeted anti-bladder cancer agents’ discovery.

N - (4 - (3 - amino - 1 H - indazole - 4 - yl) phenyl) - N' - (2 - fluoro - 5 - methylphenyl) urea intermediate preparation method

The invention provides a preparation method of N-(4-(3-amino-1H-indazol-4-yl) phenyl)-N'-(2-fluoro-5-methylphenyl) urea and an intermediate thereof. Specifically, the invention provides a preparation method of a borate ester compound as shown in a formula I, and the preparation method comprises the following steps: enabling a compound as shown in a formula III to react with a compound as shown in a formula IV to generate a compound as shown in a formula V, and enabling the compound as shown in the formula V to react with a boron reagent to generate the compound as shown in the formula I. The method has the characteristics of convenience in reaction, easiness in obtainment of the intermediate, high yield, high product purity of above 98.5%, low cost of raw materials and the like, and is suitable for industrial application.

Design, synthesis and structure-activity relationships of novel diaryl urea derivatives as potential EGFR inhibitors

Two novel series of diaryl urea derivatives 5a-i and 13a-l were synthesized and evaluated for their cytotoxicity against H-460, HT-29, A549, and MDA-MB-231 cancer cell lines in vitro. Therein, 4-aminoquinazolinyl-diaryl urea derivatives 5a-i demonstrated significant activity, and seven of them are more active than sorafenib, with IC50 values ranging from 0.089 to 5.46 μM. Especially, compound 5a exhibited the most active potency both in cellular (IC50 = 0.15, 0.089, 0.36, and 0.75 μM, respectively) and enzymatic assay (IC50 = 56 nM against EGFR), representing a promising lead for further optimization.

With anti-tumor effect of a quinazoline-urea derivative and its application (by machine translation)

The present invention relates to a of the general formula (II) anti-tumor function of said quinazoline-urea derivative and its application. The definition of the substituent in the general formula (II) in the specification. This invention, in order to SUO draw non-Buddhist nun and Geftinat compounds as the precursor, retention of SUO draw non-Buddhist nun the pharmocology-carbamido; at the same time, such as in reserved [...] EGFR-TKIs Geftinat, synthesis, and obtain a series of quinazoline-urea derivatives, by the in vitro activity tests, some compounds exhibit excellent anti-tumor activity, such derivatives have high research and utility value. (II). (by machine translation)

Synthesis of aryl urea derivatives from aryl amines and aryl isocyanates

The present study describes the synthesis of novel diaryl urea derivatives derived from aryl amine and aryl isocyanates. The synthesized compounds are analogs of sorafenib [4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl] amino]phenoxy]-N-methylpyridine-2- carboxamide] having potential antiproliferative activity.

Structural optimization of a CXCR2-directed antagonist that indirectly inhibits γ-secretase and reduces Aβ

Amyloid β (Aβ), a key molecule in the pathogenesis of Alzheimer's disease (AD), is derived from the amyloid precursor protein (APP) by sequential proteolysis via β- and γ-secretases. Because of their role in generation of Aβ, these enzymes have emerged as important therapeutic targets for AD. In the case of γ-secretase, progress has been made towards designing potent inhibitors with suitable pharmacological profiles. Direct γ-secretase inhibitors are being evaluated in clinical trials and new strategies are being explored to block γ-secretase activity indirectly as well. In this regard, we have previously reported an indirect regulation of γ-secretase through antagonism of CXCR2, a G-protein coupled receptor (GPCR). We demonstrated that N-(2-hydroxy-4-nitrophenyl)-N′-(2-bromophenyl)urea (SB225002), a selective inhibitor of CXCR2 also plays a role in an indirect inhibition of γ-secretase. Furthermore, we reported a ～5-fold difference in the selective inhibition of APP versus Notch processing via γ-secretase following treatment with SB225002. Herein we describe the synthesis and optimization of SB225002. By determination of the structure-activity relationship (SAR), we derived small molecules that inhibit Aβ40 production with IC50 values in the sub-micromolar range in a cell-based assay and also validated the potential of CXCR2 as a new target for therapeutic intervention in AD.

Parasiticidal new substituted thienopyranones

Parasiticidal new substituted thienopyranones of the formula STR1 in which X represents O or S, R1 and R2 independently of one another represent hydrogen, halogen, CN, NO2, alkyl, aralkyl, aryl, alkylcarbonyl or alkoxycarbonyl, or, together with the adjacent C atoms, form a carbocyclic ring which is optionally interrupted by heteroatoms, R3 represents optionally substituted alkyl or phenyl, R4 represents hydrogen or alkyl, R3 and R4, together with the adjacent nitrogen atom, represent a heterocyclic 5- or 6-membered ring. Some of the intermediates for making them are also new.